Ensysce Biosciences
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7946 Ivanhoe Ave Ste 201, La Jolla, Cali...Phone Number
(858) 263-4196Website
www.ensysce.comRevenue
<$5 MillionStock Symbol
ENSCIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotechnology company focused on developing innovative oral drug delivery technologies designed to improve the safety of prescription medications, particularly in the treatment of severe and chronic pain. The companys proprietary platforms aim to reduce risks of drug abuse, misuse, and overdose by using advanced chemistry-based mechanisms that control how active drug ingredients are released and activated in the body. Its research and development efforts are centered on creating safer opioid and non-opioid therapies, supported by collaborations with research institutions and industry partners.Explore more
Ensysce Biosciences Org Chart
WS
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ensysce Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ensysce Biosciences had a recent Job posting/layoffs
Earning: See what the market has to say on Ensysce Biosciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Ensysce Biosciences is spiking on competitors!
Product Launch: Get notified when Ensysce Biosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ensysce Biosciences has new funding data
Check if Ensysce Biosciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ensysce Biosciences
Ensysce Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Ensysce Biosciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Ensysce Biosciences
Compare insights from companies similar to Ensysce Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$11.5M
51-200
Private
-
1990
ML
Marlene LeuenbergerVice President and General Manager, Quotient Sciences - Philadelphia
Company Profile Activity
Activity Insights
Ensysce Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ensysce Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ensysce Biosciences.
Ensysce Biosciences financials insights
Gather financial insights about Ensysce Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$60M
2022
Debt
$8M
2026
Stock/Share Issuance
$2M
Stock/Share Issuance
$77.2M
Ensysce Biosciences Tech Stack
A closer look at the technologies used by Ensysce Biosciences
Most Recent Scoops
Funding
Funding
Person-Based
Acquisitions, Finance, Financing & Debt
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Left Company
Executive Move
Executive Moves, Left Company
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Ensysce Biosciences News & Media
Why Investors Are Watching These Healthcare Movers
$CLRO, $NTHI, $IOVA, $ENSC are covered in today’s roundupEnsysce Completes Cy Acquisition; Up to $77M Financing | ENSC Stock News
CY200 joins Ensysce with about $21.5M expected at the initial close and up to $38.6M subject to a clinical milestone; funds are expected to support Phase 2 data.Ensysce closes $2M financing under $20M agreement | ENSC Stock News
The tranche comes from a November 2025 commitment of up to $20M over 24 months, giving Ensysce capital for flagship pain programs and operations.Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript
Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call January 7, 2026 12:00 PM ESTCompany ParticipantsRobert GowerDavid Humphrey - CFO, Secretary &...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Ensysce Biosciences
Sign Up For FreeTo access detailed company insights
Ensysce Biosciences is a clinical-stage biotechnology company focused on developing innovative oral drug delivery technologies designed to improve the safety of prescription medications, particularly in the treatment of severe and chronic pain. The companys proprietary platforms aim to reduce risks of drug abuse, misuse, and overdose by using advan... Read More
